Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Recombinant Human Interleukin-11 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Recombinant Human Interleukin-11 (rhIL-11) | DRUG | - |
Inclusion Criteria: * Documented, signed and dated informed consent to participate in this trial prior to any study related procedures being performed. * Men and women age 16 years and over. * Diagnosis of Crohn's disease for at least 6 months that has been appropriately documented and confirmed by...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Risankizumab, Risankizumab On-Body Injector |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 16 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
Recombinant Human Interleukin-11 is being studied for the treatment of active Crohn Disease. It is an investigational therapy in Phase 2 clinical development, evaluated in a completed trial for patients with Crohn Disease and Inflammatory Bowel Disease. The drug has not been approved for this indication and remains in clinical investigation.
Recombinant Human Interleukin-11 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company sponsored a Phase 2 clinical trial of the drug in patients with active Crohn Disease.
Recombinant Human Interleukin-11 is in Phase 2 clinical development for Crohn Disease. A Phase 2 trial has been completed, and the drug is not FDA approved. It remains an investigational agent under study for this gastrointestinal condition.
Recombinant Human Interleukin-11 was evaluated in a completed Phase 2 trial registered as NCT00040521, titled 'Study Evaluating rhIL-11 in Active Crohn's Disease.' The trial enrolled patients aged 16 years and older in the United States with Crohn Disease or Inflammatory Bowel Disease. No active trials are currently listed.
Yes, Recombinant Human Interleukin-11 is also known as rhIL-11. The clinical trial NCT00040521 uses the abbreviation rhIL-11 in its title, referring to the same investigational drug being developed by Pfizer for active Crohn Disease.